Testing interaction between treatment and high‐dimensional covariates in randomized clinical trials

In this paper, we considered different methods to test the interaction between treatment and a potentially large number (p) of covariates in randomized clinical trials. The simplest approach was to fit univariate (marginal) models and to combine the univariate statistics or p-values (e.g., minimum p-value). Another possibility was to reduce the dimension of the covariates using the principal components (PCs) and to test the interaction between treatment and PCs. Finally, we considered the Goeman global test applied to the high-dimensional interaction matrix, adjusted for the main (treatment and covariates) effects. These tests can be used for personalized medicine to test if a large set of biomarkers can be useful to identify a subset of patients who may be more responsive to treatment. We evaluated the performance of these methods on simulated data and we applied them on data from two early phases oncology clinical trials.

[1]  Bart Spiessens,et al.  Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  John Crowley,et al.  Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine , 2012, Clinical Cancer Research.

[3]  Jelle J. Goeman,et al.  A global test for groups of genes: testing association with a clinical outcome , 2004, Bioinform..

[4]  Lihui Zhao,et al.  A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies. , 2016, Biometrics.

[5]  Wei Pan,et al.  Asymptotic tests of association with multiple SNPs in linkage disequilibrium , 2009, Genetic epidemiology.

[6]  R. Simon,et al.  Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients , 2005, Clinical Cancer Research.

[7]  Qi Liu,et al.  BMC Bioinformatics BioMed Central Methodology article Comparative evaluation of gene-set analysis methods , 2007 .

[8]  Lu Tian,et al.  A Simple Method for Detecting Interactions between a Treatment and a Large Number of Covariates , 2012, 1212.2995.

[9]  T. Treasure,et al.  Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Donglin Zeng,et al.  Estimating Individualized Treatment Rules Using Outcome Weighted Learning , 2012, Journal of the American Statistical Association.

[12]  R. Simon,et al.  The Cross-Validated Adaptive Signature Design , 2010, Clinical Cancer Research.

[13]  Jelle J. Goeman,et al.  Testing association of a pathway with survival using gene expression data , 2005, Bioinform..

[14]  H. Putter,et al.  Dynamic Prediction in Clinical Survival Analysis , 2011 .

[15]  Wei Pan,et al.  Adaptive Tests for Detecting Gene-Gene and Gene-Environment Interactions , 2011, Human Heredity.

[16]  J. Goeman,et al.  The Inheritance Procedure: Multiple Testing of Tree-structured Hypotheses , 2012, Statistical applications in genetics and molecular biology.